Research brief · not an official record
Case no. ÖH-2026-0819 · Exhibits 1–6
Seal: eye in a gold ring on a navy field

Eye Health

Vitreous · retina · oxidative evidence

Compiled 19 August 2026
Ten parallel research agents
List of sources
Ceremonial hall in navy, gold and parchment
A brief in Swedish court-document tone · original seal, not the arms of the Svea Court of Appeal

Floaters are common. They are not always harmless.

Most floaters are age-related changes in the vitreous. A smaller share are the early warning of retinal detachment. This page ranks what the evidence actually supports — not what marketing claims.

The vitreous is a collagen-and-hyaluronan gel that fills most of the eye. When the gel liquefies (syneresis) and collagen fibres clump together, they cast shadows on the retina — what you see as flies, threads or veils.

Evidence grades: A RCT · B observational · C mechanism · D expert/market Not medical advice Updated 2026-08-19

Exhibit 1 Prioritised health gain — what actually counts

Ranking = expected benefit × evidence quality × safety, after the retina has been examined. Observation remains standard care for uncomplicated floaters.

  1. New, sudden or increasing swarm + flashes / curtain → ophthalmologist the same day

    A/B clinical standardVision-critical

    Retinal-tear risk is real in those who present acutely. The relative risk of later detachment was 17.7 after a confirmed tear in the Swedish cohort. Time to effect: hours. No dietary measure replaces this.

  2. Stop smoking, blood pressure, blood sugar — systemic eye health

    A AMD/vascularC vitreous

    Strongest for macular degeneration and diabetic retinopathy, not for the vitreous specks themselves. But the retina is one of the body's most metabolically demanding organs. Time: weeks–years.

  3. Daylight outdoors, darkness at night, sleep

    B circadian / myopiaC mitochondria

    Outdoor light is evidence-bearing for childhood myopia and circadian rhythm. Blue-light glasses against floaters are weakly supported. Don't trade away daylight for filter lenses.

  4. AREDS2-class formula if you have intermediate-to-late AMD risk

    A AREDS/AREDS2

    Lutein 10 mg + zeaxanthin 2 mg, C, E, zinc, copper. Reduces progression to late AMD in the right patients (~25% in the original AREDS for high risk). Not a floater cure. High zinc (80 mg) caused stomach upset; 25 mg is an alternative in AREDS2.

  5. Dietary ascorbate — the vitreous's main antioxidant

    B biochemistryC floaters

    Vitamin C in the vitreous sits around 2 mM — on the order of 20–40× plasma — and consumes oxygen at the vitreoretinal interface. Avoiding deficiency is reasonable. Megadosing against floaters is not shown.

  6. Targeted FLIES-type micronutrient support (lysine, C, grape extract, zinc, citrus)

    A one RCT, n=61

    FLIES (Ankamah et al. 2021): 66.6% vs 26.9% placebo achieved the desired effect on a non-validated questionnaire. 76.9% vs 28.6% had any reduction in measured area — that is the responder rate, not the area shrinking by 77%. Mean area fell about 18% (121 → 100 cm²). Funding ebiga-VISION/WIT, patent. Not standard care.

  7. Proteolytic enzymes (bromelain 190 mg, papain 95 mg, ficin 95 mg)

    B/A same research group

    Ma et al. 2022: 55 / 62.5 / 70% “disappeared” at 1 / 2 / 3 capsules. The 92% “bright” figure is a satisfaction measure without a placebo split — not the efficacy endpoint. Same group as the pineapple study; first author linked to Unique Biotechnology; no independent replication; data inconsistencies in the tables. Evidence: very low. Not advice.

  8. Pineapple as food — weaker than the capsules

    C/pilot

    Horng 2019: pineapple pieces, no control group. The hypothesis is bromelain against collagen aggregates. Safe food, uncertain effect. Not a substitute for an eye exam.

  9. Taurine, B2, B3, selenium, zinc via food

    C retinaD floaters

    Mechanistically plausible cofactors for antioxidant enzymes and photoreceptors. Clinical floater data is lacking. Taurine is enriched in the retina. Avoid high copper/zinc doses without cause.

  10. Blue-light glasses “where appropriate”

    D for floatersC phototoxicity in animals

    Retinal cells are light-sensitive in the lab. Screen blue light is not shown to create vitreous floaters. Amber glasses in the evening may help sleep; daytime outdoors matters more.

  11. Fewer seed oils / “excess PUFA”

    D speculative for floaters

    Systemic inflammation and oxidised lipids are plausible in metabolic disease. There are no human RCTs showing that cutting seed oil reduces floaters. Do not place this ahead of an exam, smoking cessation or shown supplements.

  12. Vitrectomy / YAG vitreolysis — only for severe suffering

    A surgeryRisk

    The definitive treatment is pars plana vitrectomy. Risks: cataract, retinal detachment, raised pressure. YAG lacks robust long-term data. Wagle et al.: some patients would trade ~1.1 of 10 remaining life-years to be rid of floaters — that justifies a conversation, not routine surgery.

Exhibit 2 Charts — eye health against age and against the studies

Two facts in one picture: the vitreous liquefies with age, and the two most-cited supplement studies are not equal in design.

Posterior vitreous detachment (PVD) rises steeply with age

Itakura & Kishi 2013, complete PVD (OCT stage 4) in living eyes: 2% at 40–49, 14% at 50–59, 44% at 60–69, 80% at 70–79, 95% at 80–89. PVD is not the same as all floaters — younger people can see floaters without a complete detachment. Autopsy series (Foos) give lower figures.

Complete PVD, OCT (%)
% 40–49 2 50–59 14 60–69 44 70–79 80 80–89 95

What the studies showed — not what the email simplified

FLIES 76.9% = the share whose area decreased at all (placebo 28.6%); mean area about −18%, not −50%. The enzyme study's 92% “bright” is satisfaction, not an imaging measure, and lacks a placebo split.

Active treatment Placebo / control
0        25       50       75      100 % FLIES less discomfort 66.6% 26.9% FLIES less opacity 76.9% 28.6% Enzymes 1 / 2 / 3 caps. 55% 62.5% 70% Ma 2022 “bright” 3 mo 92%

Exhibit 3 What the vitreous is — and why oxidative stress is mentioned

Structure

About 99% water, ~0.5% collagen (mainly type II) and ~0.5% hyaluronan. It attaches most firmly at the optic disc, macula and ora serrata. When the gel collapses it can tug on the retina — flashes — or release a Weiss ring.

Mechanisms

Oxidative stress, reduced antioxidant capacity and glycation (AGE) are proposed to drive collagen aggregation and hyaluronan depolymerisation. High myopia, menopause and certain collagen disorders (e.g. Stickler) raise the risk.

The email's thesis — that floaters may be an early marker of systemic oxidative stress — is possible but not proven. Ordinary age-related floaters are well explained by local gel ageing. It is true, however, that the same antioxidant network (C, zinc, selenium-dependent enzymes) protects both the eye and other tissues.

Floaters do not vanish simply because you “get used to them”. The FLIES authors note that saccades and increased fluidity keep the opacities from settling out of view.

Exhibit 4 The two study lines, read carefully

ItemFLIES / VitroCap NBromelain–papain–ficin
SourceAnkamah et al., TVST 2021, PMC8525826Ma et al., J Clin Med 2022, PMID 36431188
DesignDouble-blind RCT, placebo, 6 moDouble-blind, dose groups, 3 mo
n61 randomised, 56 analysed224 with monocular SVO
Dose125 mg L-lysine, 40 mg C, 26.3 mg Vitis vinifera, 5 mg zinc, 100 mg Citrus aurantium daily190 / 95 / 95 mg per capsule, 1–3/day
Main finding66.6% vs 26.9% better category; 76.9% vs 28.6% any area reduction; mean area about −18%55–70% “disappeared”; 92% “bright” without a placebo split
LimitationSmall n, non-validated questionnaire, manufacturer funding, patentSame group as pineapple studies; no independent replication

The VitroCap N line also has observational studies (Heidelberg 2013, Minsk 2015, Warsaw 2018, St Petersburg 2019). They are supportive but weaker than FLIES. The 2019 pineapple study is an uncontrolled pilot.

Exhibit 5 Nutrients — what is shown for the eye

NutrientRoleWhat is shownGrade
Vitamin CMain antioxidant in the vitreous (~2 mM)Biochemistry strong; floater RCT only as part of FLIES (40 mg)B/C
Lutein / zeaxanthinMacular pigmentAREDS2: 10 + 2 mg replaces beta-caroteneA AMD
ZincRetina, metallothionein, AGE protectionAREDS 80 mg; AREDS2 also 25 mg. FLIES 5 mgA AMD / C floaters
Vitamin APhoto-cycleDeficiency causes night blindness; overdose harmfulA deficiency / D floaters
B2, B3Glutathione / NAD in the retinaMechanism; no floater RCTC
SeleniumGlutathione peroxidaseMechanism; toxicity windowC
TaurineHigh concentration in the retinaAnimal/mechanism; human floater data lackingC
Copper, manganeseSOD cofactorsAREDS adds 2 mg Cu against zinc-induced deficiencyA as cofactor
Omega-3AREDS2: no extra AMD benefitNot a floater treatmentA negative for AMD add-on

Exhibit 6 Light, mitochondria, inflammation

The retina has an extremely high metabolic rate and uses glucose; insulin aids uptake in several ocular tissues. When metabolism falters, oxygen can accumulate and oxidants rise — a plausible bridge between metabolic disease and eye damage, shown most strongly for diabetic retinopathy, not for ordinary floaters.

Blue light can damage mitochondria in animal and cell models. Population data do not link ordinary screen use to vitreous degeneration. On the other hand: more daylight outdoors, less evening LED in the bedroom, and sleep are harmless and generally beneficial advice.

Iron overload is relevant with bleeding into the vitreous (iron catalyses Fenton reactions) — not as everyday advice to “detox iron”. The gut and seed oils as a primary cause of floaters is speculative; they belong in a metabolic-health discussion, not as a first-line measure here.

Sources Selection — full list on the sources page

  1. Itakura H, Kishi S. Evolution of PVD with age in normal Japanese eyes. JAMA Ophthalmol. 2013. OCT prevalence per decade.
  2. Ankamah E et al. Dietary intervention with a targeted micronutrient formulation… Transl Vis Sci Technol. 2021. PMC8525826
  3. Ma JW et al. Mixed fruit enzymes for ocular floaters or vitreous hemorrhage-induced floaters. J Clin Med. 2022. PMID 36431188
  4. Bond-Taylor M, Jakobsson G, Zetterberg M. Posterior vitreous detachment – prevalence of and risk factors for retinal tears. Clin Ophthalmol. 2017. Sahlgrenska. PMC5609787
  5. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3… JAMA. 2013. AREDS2.
  6. Hollands H et al. Acute-onset floaters and flashes. JAMA. 2009.
  7. Wagle AM et al. Utility values associated with vitreous floaters. Am J Ophthalmol. 2011.
  8. McGill OSS. Pineapple for eye floaters: sweet deal or pipe dream? 2021. mcgill.ca/oss

All sources and evidence grades →

This page is not the Svea Court of Appeal, not the Courts of Sweden and not medical care. It borrows the courts' colour and typography language (navy #1c1f66, gold #fab834, Open Sans + Georgia) as a research aesthetic. Official coats of arms are not used.